

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

LIQUIDIA TECHNOLOGIES, INC.,

Petitioner

v.

UNITED THERAPEUTICS CORPORATION,

Patent Owner.

Case IPR2020-00769

Patent No. 9,593,066

**Patent Owner's Mandatory Notices
Under 37 C.F.R. § 42.8**

IPR2020-00769	Patent Owner Mandatory Notices
U.S. Patent No. 9,593,066	

Pursuant to 37 C.F.R. § 42.8, United Therapeutics Corporation (“United Therapeutics”) provides this Mandatory Notice within 21 days of service of the Petition (Paper 1) on March 31, 2020.

I. Real Party-in-Interest Pursuant to 37 C.F.R. § 42.8 (b)(1):

United Therapeutics is the sole owner of U.S. Patent No. 9,593,066 (the “’066 patent”).

II. Related Matters Pursuant to 37 C.F.R. § 42.8 (b)(2):

US Ser. No. 16/594,737 is a pending continuation application with common priority to the ‘066 patent. IPR2020-00770 involves U.S. Patent No. 9,604,901 (the “’901 patent”), a patent with common priority to the ‘066 patent. United Therapeutics is not aware of any other related matters involving the ‘066 patent.

III. Lead and Back-Up Counsel Pursuant to 37 C.F.R. §§ 42.8(b)(3):

United Therapeutics designates the following Lead and Back-up Counsel:

Lead Counsel:

Stephen B. Maebius
Foley & Lardner LLP
3000 K St., NW, Suite 600
Washington, DC 20007
Direct Line: 202-672-5569
Email: smaebius@foley.com
Fax: 202-672-5399
USPTO Reg. No. 35,264

IPR2020-00769	Patent Owner Mandatory Notices
U.S. Patent No. 9,593,066	

Backup Counsel:

George Quillin
Foley & Lardner LLP
3000 K St., NW, Suite 600
Washington, DC 20007
Direct Line: 202-672-5413
Email: gquillin@foley.com
Fax: 202-672-5399
USPTO Reg. No. 32,792

Daniel R. Shelton
Foley & Lardner LLP
975 Page Mill Rd.
Palo Alto, CA 94304
Direct Line: 650-251-1119
Email: dshelton@foley.com
Fax: 650-856-3710
USPTO Reg. No. 68,519

Shaun R. Snader
United Therapeutics Corp.
1735 Connecticut Ave., NW, 2nd Floor
Washington, DC 20009
Direct Line: 202-304-1701
Email: ssnader@unither.com
USPTO Reg. No. 59,987

Douglas Carsten
Wilson, Sonsini, Goodrich & Rosati
12235 El Camino Real
Suite 200
San Diego, CA 92130
Direct Line: 858-350-2305
Email: dcarsten@wsgr.com
Fax: 858-350-2399
USPTO Reg. No. 43,534

IPR2020-00769	Patent Owner Mandatory Notices
U.S. Patent No. 9,593,066	

Richard Torczon
Wilson, Sonsini, Goodrich & Rosati
1700 K Street NW, Floor 5
Washington, DC 20006
Direct Line: 202-973-8811
Email: rtorczon@wsgr.com
Fax: 202-973-8899
USPTO Reg. No. 34,448

IV. Service Information Pursuant to 37 C.F.R. §§ 42.8(b)(4):

Please address all correspondence to the lead counsel at the address shown above. Patent Owner consents to electronic service by e-mail at:

SMaebius@foley.com and UTC-066@foley.com

Any questions concerning this paper may be directed to lead counsel.

Dated: April 17, 2020

Respectfully submitted,

/Stephen B. Maebius/
Stephen B. Maebius
Registration No. 35,264
Counsel for Patent Owner

IPR2020-00769	Patent Owner Mandatory Notices
U.S. Patent No. 9,593,066	

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing **United Therapeutics Corporation's Mandatory Notices Under 37 C.F.R. § 42.8** was served on April 17, 2020, by email directed to the attorneys of record for the Petitioner at the following addresses:

zLiquidiaIPR@cooley.com¹
ielrifi@cooley.com
emilch@cooley.com
dkannappan@cooley.com

Dated: April 17, 2020

By: /Stephen B. Maebius/
Stephen B. Maebius
Registration No. 35,264
Counsel for Patent Owner

¹ Patent Owner notes that this email address is listed in the petition filed against the '066 patent but not in the petition filed against the '901 patent.